2026-04-17T23:28:22Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/118582025-10-24T10:16:58Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
DE HARO DEL MORAL, F JAVIER
author
Aguade Bruix, Santiago
author
Tabuenca Mateo, Maria Josefa
author
TAMAYO ALONSO, M. PILAR
author
Mohamed-Salem, Laroussi
author
Bernal, Laura
2025-10-24T10:16:58Z
2025-10-24T10:16:58Z
2024-08-22T10:22:48Z2024-08-22T10:22:48Z2024-05-29
http://hdl.handle.net/11351/11858
Bone scintigraphy; Cardiac amyloidosis; Incidental cardiac uptakeGammagrafia òssia; Amiloïdosi cardíaca; Captació cardíaca incidentalGammagrafía ósea; Amiloidosis cardíaca; Captación cardíaca incidentalAim
Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.
Methods and results
This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with >50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1–15.7). All were >70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (p < 0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p = 0.025).
Conclusions
This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.This study was sponsored by Pfizer SLU. Pfizer contributed to the design of the project and writing of the manuscript under the supervision of the rest of the authors.
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Neuropatia
Miocardi - Malalties
Gammagrafia
Ossos - Imatgeria
DISEASES::Nervous System Diseases::Neurodegenerative Diseases::Heredodegenerative Disorders, Nervous System::Amyloid Neuropathies, Familial
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
DISEASES::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Radionuclide Imaging
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades neurodegenerativas::trastornos heredodegenerativos del sistema nervioso::neuropatías amiloideas familiares
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::imagen radioisotópica
Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion